Streetbeat News

Analyst Ratings

ZS

Rosenblatt analyst Catharine Trebnick maintains a Buy rating on Zscaler (NASDAQ:ZS) and raises the price target from $245 to $285.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:23 pm

SNPS

Rosenblatt analyst Blair Abernethy has maintained a Buy rating on Synopsys (NASDAQ:SNPS) and increased the price target from $570 to $615.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:20 pm

CRWD

Rosenblatt analyst Catharine Trebnick maintains a Buy rating on CrowdStrike Holdings (CRWD) and raises the price target from $315 to $375.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:15 pm

DOW

IP

KALU

Wall Street's most accurate analysts have provided their views on three high-dividend yielding stocks in the materials sector: International Paper Company (IP), Dow Inc. (DOW), and Kaiser Aluminum Corporation (KALU). These stocks offer dividend yields of 5.17%, 5.05%, and 4.66% respectively. Recent updates include IP's Q4 sales missing analyst consensus, Dow's completion of a green bond offering, and Kaiser Aluminum's upcoming financial results announcement.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 1:14 pm

NVDA

Rosenblatt analyst Hans Mosesmann reiterates a Buy rating on NVIDIA (NASDAQ:NVDA) and maintains a $1100 price target.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:07 pm

DYN

HC Wainwright & Co. analyst Andrew Fein initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating and a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:03 pm

UDR

Analyst ratings for UDR, Inc. (NYSE:UDR) show a mix of sentiments, with recent evaluations ranging from bullish to bearish. Over the last quarter, 4 analysts have provided ratings, with a current average 12-month price target of $38.5, a decrease from the prior average of $41.50. Analyst actions include both downgrades and upgrades, reflecting dynamic market conditions and UDR's performance. UDR, a real estate investment trust, has shown notable revenue growth and financial performance, with a market capitalization above industry average, a revenue growth rate of 0.77%, and strong profitability indicators such as a net margin of 7.69%, ROE of 0.79%, and ROA of 0.28%.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 1:01 pm

ZI

Analyst ratings for ZoomInfo Technologies (NASDAQ:ZI) show varied opinions over the last quarter, with a shift towards more positive ratings in the recent 30 days. The average 12-month price target for ZI has increased to $21.15, up 4.44% from the previous target. The company's financial performance indicates solid revenue growth but challenges in profitability and efficiency, with a net margin of -1.74% and ROE of -0.25%. Analysts' actions, ranging from maintaining to raising or lowering ratings, reflect their response to ZoomInfo's market conditions and performance.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 1:00 pm

ELEV

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Elevation Oncology (NASDAQ:ELEV) and raises the price target from $1.5 to $6.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:56 pm

IOVA

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and raises the price target from $28 to $32.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:52 pm